retatrutide phase 2 results obesity nejm 2023 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released trial demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide study sees significant weight
Description
Consuming soda at or near the time of dosing will significantly reduce medication absorption and effectiveness
Theyve been standard treatments for diabetes, so theyve been out and about for 20 years or so
The Saxenda SmPC (emc) should be consulted for full safety information
Rapid weight loss spurred by a GLP-1 and shes not the only one
But once you stop, those benefits fade if your habits dont stick
Your healthcare provider must evaluate your medical history regardless of which manufacturer's product you consider
